The Cross-Border Biotech Blog

Part_2_BiotechBlackBox

Some basic mathematics   When you create a valuation spreadsheet, you are plugging in estimates of revenues and expenses which are going to occur over several years, if not a couple decades. When you do the basic addition and subtraction in this spreadsheet, you hopefully end up with a positive number because, if the number […]

read more


Apollo_Part1

Email: snicolle@capebearadvisors.com   Specialty Drugs and Preferred Pharmacy Networks in Canada   In the most recent episode of Downton Abbey  (empathy watch with my wife and because the latest season of Trailer Park Boys isn’t out yet), the crusty veteran village doctor mentions the discovery of insulin and how a diabetes diagnosis “might no longer […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for January 26th, 2015!   This week saw significant activity on the financing front, with EnGene announcing $13.5 million in series B funding, ESSA Pharma raising about $12 million via private placement and CohBar Inc. raising about $11.25 million an additional $2.7 million via an IPO and private placement, […]

read more


Q4Banner2

    No momentum in Q4 2014 for the smaller companies in the Canadian Healthcare Sector (Part 2) In this blog, I am going to comment on the Q4 and yearly 2014 share price performance of the group of Canadian healthcare companies which had share prices of between $0.10 and $0.99 to start 2014. Q4 […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for January 19th, 2015!     This week saw Valeant make news with details on its $1 billion senior unsecured note offering and its approximately $500 million senior note redemption. For more details on these stories, as well as many more, keep reading! Centric Health Corporation (“Centric Health”) (TSX: […]

read more


David_Allan_Title

  “Australia excels in biomedical research but sucks at commercialisation.” Prof Frank Gannon, CEO & Director of QIMR Berghofer Medical Research We may not be able to turn a phrase quite as elegantly as Dr. Gannon but what rings true for him, a leader in the drive for the commercialization of Australia’s life-sciences basic research, […]

read more


Part_1_BiotechBlackBoxes_Final

Introduction   In mid-2011 I started a 26-part blog series titled ‘Valuation & Other Biotech Mysteries’. Some aspects of the valuation blogs have not changed, such as NPV calculations. Other aspects have changed substantially – and will continue to change, such as the state of capital markets, investor interest in biotech, reimbursement problems, and the […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for January 12th, 2015!   *A day late, but here is the Monday Deal Review for January 12 Happy new year! This week’s post covers deal activity stretching over the holiday season, and therefore covers a lot of ground.  Keep reading for a review of Canadian biotech’s major deal […]

read more


Q4Banner1

    Quietly positive Q4 over-shadowed by broader Canadian market volatility Individual company and sector share price performance in Q3 and Q4 was impacted by volatility in the broader Canadian market. Broad market decline straddling the end of Q3 / beginning of Q4 Broad market decline in early December triggered by collapsing oil prices and […]

read more